中华皮肤科杂志 ›› 2010, Vol. 43 ›› Issue (8): 583-585.

• 论著 • 上一篇    下一篇

卡介菌多糖核酸对特应性皮炎患者外周血T淋巴细胞表达细胞因子的影响

张丽1,狄正鸿2,马蕾3,陈洪铎4,高兴华5   

  1. 1. 中国医科大学附属第一医院
    2. 沈阳中国医科大学附属盛京医院皮肤科
    3. 滨州医学院附属医院皮肤科
    4. 中国医科大学第一附属医院皮肤科
    5. 沈阳 中国医科大学附属第一医院皮肤科
  • 收稿日期:2009-12-07 修回日期:2010-04-02 出版日期:2010-08-15 发布日期:2010-08-10
  • 通讯作者: 张丽 E-mail:blanka33@163.com
  • 基金资助:

    教育部长江学者和创新团队发展计划资助项目;辽宁省创新团队资助项目;辽宁省创新团队资助项目

Effect of bacille calmette-guerin polysaccharide nucleic acid （BCG-PSN） on the expression of T cell-derived cytokines in patients with atopic dermatitis

  • Received:2009-12-07 Revised:2010-04-02 Online:2010-08-15 Published:2010-08-10
  • Contact: ZHANG LI E-mail:blanka33@163.com

PDF

167

赞

摘要：

目的 探讨卡介菌多糖核酸治疗前后特应性皮炎（AD）患者外周血表达不同细胞因子的T淋巴细胞频数及其与疾病严重程度的相关性。方法 以双盲、随机、交叉对照方法治疗AD患者，应用流式细胞术检测治疗前后8例AD患者外周血T淋巴细胞内细胞因子IL-4、IL-5、IFN-γ、TNF-α的表达；利用AD皮损面积严重度指数积分（ADASIS）评价AD患者病情严重程度。结果 治疗组IFN-γ+CD8+ T淋巴细胞频数差值为（8.06 ± 13.96）%，较之安慰剂组（-6.55 ± 10.49）%明显升高（U = 2.26，P < 0.05），表达其他细胞因子的T细胞频数在两组间差异无统计学意义（P > 0.05）。治疗组ADASIS积分下降值为1.56 ± 1.49，高于安慰剂组（-0.05 ± 1.54），U = 2.00，P < 0.05。结论 卡介菌多糖核酸可能通过纠正T淋巴细胞亚群的免疫失衡状态治疗AD。

关键词: 特应性皮炎, 卡介菌多糖核酸, 细胞因子

Abstract:

Objective To assess the changes in frequency of peripheral T lymphocytes expressing different cytokines in patients with atopic dermatitis （AD） before and after treatment with BCG-PSN and their relationship with disease severity. Methods A randomized, double blinded and placebo cross-over control study was conducted. A total of 8 patients with AD were recruited in this study. Intramuscular BCG-PSN or placebo was given to patients every other day for 36 days. Flow cytometry was performed to measure the frequency of IL4-, IL5-, IFNγ- and TNFα-expressing peripheral CD4+ T cells and CD8+ T cells before and after the therapy. Disease severity was evaluated by atopic dermatitis area and severity index score （ADASIS）. Results The difference value in IFN-γ+CD8+ T cell frequency before and after therapy was significantly higher in patients treated with BCG-PSN than in those with placebo （8.056 ± 13.962 vs -6.549 ± 10.491, U = 2.26, P < 0.05）. There was no statistical difference in the frequency of IL4-, IL5-, TNFα-expressing CD8+ T cells between BCG-PSN- and placebo-treated patients （all P > 0.05）. The decrease in ADASIS was 1.56 ± 1.49 in patients treated with BCG-PSN, which was statistically higher than that in placebo-treated patients （-0.05 ± 1.54, U = 2.00, P < 0.05）. Conclusion As an immunomodulator, BCG-PSN may control AD by restoring the balance of T-cell subsets.

Key words: atopic dermatitis, polysaccharide and nucleoside extract from Calmett- Guirin, cytokines